Research
FORUM TRANSCRIPT

CGM Market – Q4 2022 Update & Commercial Execution

  • Public Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former regional leader at Abbott Laboratories

Agenda

  • Recent trends and developments within the broader diabetes and CGM (continuous glucose monitor) industry
  • Comparative analysis of Dexcom’s (NASDAQ: DXCM) G7 and Abbott’s (NYSE: ABT) FreeStyle Libre 3 franchise
  • Sensor usage timeline and cost-reduction advantages of extending wear time
  • Type 2 diabetes awareness and adoption strategies utilised by organisations to drive further CGM penetration
  • Relative sales force reputations and execution in CGM product placements
  • 2023 M&A outlook, untapped growth opportunities and strategic assessments

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo